MindMed to Host Investor Day June 2023
07 Junho 2023 - 9:00AM
Business Wire
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED),
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today that its management team will a host an
Analyst Day in New York City on Tuesday, June 20th, 2023 that will
focus on the MM-120 program in generalized anxiety disorder (GAD).
In person attendance is by invitation only. All others are invited
to participate via the live webcast.
MindMed’s 2023 Analyst Day
Date and Time: June 20th, 2023 at 9:30am ET Registration:
Virtual Registration Link
Audio webcasts and replays of available presentations will be
accessible on MindMed’s Investor Resources website for up to
90 days following the event.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230607005238/en/
For Media & Investor Inquiries: Maxim Jacobs, CFA Vice
President, Investor Relations and Corporate Communications Mind
Medicine (MindMed) Inc. ir@mindmed.co
media@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024